Serina Therapeutics Inc (SER) Q1 2026 Earnings Report

Serina Therapeutics reported a Q1 2026 result that continues to reflect the company’s status as a pre-revenue biotechnology firm in the early stages of drug development. The quarter ended March 31, 2026, showed a net loss of $6.94 million, driven entirely by operating expenses in the absence of revenue. R&D and general and administrative costs totaled $6.28 million, with R&D at $3.199 million and G&A at $3.081 million, contributing to a diluted loss per share of $0.58. The company also leveraged debt-like interest expense of $0.189 million, while basic metrics such as revenue remain unavailable in QQ1 2026 data.

From a strategic standpoint, Serina continues to pursue its lead candidate SER-252 (a POZ conjugate for Parkinson’s disease) along with a broader pipeline (SER-227, SER-214, SER-228) and POZ technology initiatives. While the quarter provides limited visibility into near-term commercial traction, investors should monitor clinical milestones, data readouts, and potential financing activities that could impact liquidity given the current burn profile. Notably, the number of weighted average shares outstanding rose to 12.047 million in QQ1 2026 from 9.756 million in QQ1 2025, indicating dilution that contributed to the per-share loss despite a higher headcount of outstanding shares.

Overall, the QQ1 2026 results underscore the high-risk, high-reward nature of Serina’s business model: substantial R&D investment with meaningful clinical upside if pipeline programs advance, but continued cash burn and uncertainty until clinical data translate into value events.